Date: 2015-05-21
Type of information: Milestone
Compound: S-588410
Company: OncoTherapy Science (Japan) Shionogi (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism: peptide
Disease: esophageal cancer
Details: * On February 23, 2015, OncoTherapy Science announced that OncoTherapy and Shionogi have agreed on Phase III clinical trial of the cancer-specific peptide vaccine S-588410, which OncoTherapy has out-licensed to Shionogi, for esophageal cancer, for collaborative effort on the clinical development of S-588410. Shionogi will conduct a multicenter, randomized, double-blind, placebo-controlled, comparative Phase III clinical trial of S-588410 as adjuvant therapy for esophageal cancer.
Financial terms: OncoTherapy and Shionogi will modify the milestone setting in the Clinical Trial that was defined by the license agreement between both parties on March 29, 2012, and OncoTherapy will receive from Shionogi development milestone payments defined by the Agreement according to the progress stage of the Clinical Trial. OncoTherapy will pay for part of the expenses of the Clinical Trial.
Latest news: * On May 21, 2015, OncoTherapy Science announced that Shionogi has enrolled the first patient in the Phase III clinical trial of the cancer-specific peptide vaccine S-588410, which OncoTherapy has out-licensed to Shionogi, for esophageal cancer. OncoTherapy received notification of the achievement of a milestone from Shionogi in connection withthe progress of the clinical trial, under the agreement between both parties announced on February 23, 2015.
